PRQR stock Statistics — ProQR Therapeutics N.V. filings, insiders & smart money

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2025-12-31 · filed common shares: 105.36M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.76%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 2.34%
Short ratioDays to cover, as published by FINRA: 2.08
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 54.00%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 53.00%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Sign in

Avg volume (3 months)

Gross margin: —
Operating marginFY Dec 25: -273.14%
Net margin: —
EBITDA margin: —
Return on equityNet income (FY Dec 25) ÷ average shareholders equity: -61.17%
Return on assetsNet income (FY Dec 25) ÷ average total assets: -30.05%

Sign in

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, FY Dec 25

-0.40

EPS (fwd)

Cash & equivalentsas of Dec 25: EUR 92.41M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Dec 25: EUR 15.96M
Debt / equityas of Dec 25: 32.33%
Current ratioas of Dec 25: 3.09
Quick ratio(Cash + marketable securities + receivables) ÷ current liabilities, as of Dec 25: 3.06
Operating cash flowFY Dec 25: -EUR 52.79M
Free cash flowUnadjusted FCF = CFO − capex · FY Dec 25: -EUR 53.81M
TTM revenue / diluted shareDiluted, FY Dec 25: 0.15